BioCentury | Nov 7, 2014
Top Story

Salix hit on accounting turmoil

...It singled out broad-spectrum antibiotic Xifaxan and ulcerative colitis treatments Apriso granulated mesalamine and Uceris budesonide rectal foam...
BioCentury | Nov 3, 2014
Clinical News

Cortiment MMX budesonide regulatory update

...Japan (see BioCentury, Oct. 15, 2007 & Dec. 22, 2008). Salix markets the drug as Uceris...
...S.p.A. (SIX:COPN), Lainate, Italy Ferring Pharmaceuticals A/S , Saint-Prex, Switzerland Product: Cortiment MMX budesonide ( Uceris...
BioCentury | Oct 13, 2014
Clinical News

Uceris budesonide rectal foam regulatory update

...FDA granted final approval to Uceris budesonide rectal foam from Salix for the induction of remission in patients...
...Salix plans to launch the product next quarter. Salix markets a once-daily tablet formulation of Uceris...
...Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Dr. Falk Pharma GmbH , Freiburg, Germany Product: Uceris budesonide rectal foam...
BioCentury | Oct 9, 2014
Company News

FDA approves Uceris rectal foam

...FDA approved an NDA for Uceris budesonide rectal foam from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to induce remission of...
...formulation of the glucocorticosteroid in 1Q15. The company currently markets a once-daily tablet formulation of Uceris...
...Santarus licensed Uceris from Cosmo Pharmaceuticals S.p.A. (SIX:COPN) in 2008. Also on Wednesday, Cosmo said Uceris...
BioCentury | Oct 6, 2014
Clinical News

Uceris budesonide rectal foam regulatory update

...FDA granted tentative approval to an NDA for Uceris budesonide rectal foam from Salix for the induction of...
...quarter and launch Uceris rectal foam in 1Q15. Salix markets a once-daily tablet formulation of Uceris...
...Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Dr. Falk Pharma GmbH , Freiburg, Germany Product: Uceris budesonide rectal foam...
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...methylene blue MMX and Uceris budesonide MMX - as well as Japanese patents for Uceris...
BioCentury | Jul 14, 2014
Company News

Salix Pharmaceuticals Ltd, Cosmo deal

...methylene blue MMX and Uceris budesonide MMX - as well as Japanese patents for Uceris...
...East, excluding Australia and New Zealand. Salix already has U.S. rights to ulcerative colitis drug Uceris...
...blue delivered using MMX technology - is in Phase III testing to detect colorectal cancer. Uceris...
BioCentury | Jul 10, 2014
Company News

Salix, Cosmo subsidiary to merge

...methylene blue MMX and Uceris budesonide MMX -- as well as Japanese patents for Uceris...
...due to Cosmo under a prior deal granting Salix U.S. rights to ulcerative colitis drug Uceris...
BioCentury | Feb 10, 2014
Company News

Cosmo drug delivery, gastrointestinal news

...to develop and commercialize rifamycin SV MMX and Uceris budesonide MMX under a 2008 deal. Uceris...
BioCentury | Feb 3, 2014
Clinical News

Budesonide rectal foam regulatory update

...40 cm from the anal verge. The PDUFA date is Sept. 15. Dr. Falk markets budesonide rectal foam...
...2008). Salix Pharmaceuticals Inc. (NASDAQ:SLXP), Raleigh, N.C. Dr. Falk Pharma GmbH , Freiburg, Germany Product: Budesonide rectal foam...
Items per page:
1 - 10 of 48